Erbitux as a milestone in the cancer therapy to launch in Korea.

Published: 2006-05-03 06:56:00

Updated: 2006-05-03 06:56:00

Merck Korea, a subsidiary of German Merck, launched Erbitux (Cetuximab), a new dimensional anti-cancer drug, into Korean markets on April 28 for the treatment of patients with spreaded colon cancer who are positive with EGF receptors but not responded to Irinotecan and other conventional chemothe...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK